Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis

This study has been terminated.
(Problems to recruit the needed number of patients in the planned time)
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Claudio Gobbi, Ospedale Civico, Lugano
ClinicalTrials.gov Identifier:
NCT01701856
First received: September 18, 2012
Last updated: January 21, 2014
Last verified: January 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2013
  Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)